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Abstract
While significant medical breakthroughs have been achieved through using animal models,
our experience shows that often there is surplus material remaining that is frequently never
revisited but could be put to good use by other scientists. Recognising that most scientists
are willing to share this material on a collaborative basis, it makes economic, ethical, and
academic sense to explore the option to utilise this precious resource before generating
new/additional animal models and associated samples. To bring together those requiring
animal tissue and those holding this type of archival material, we have devised a framework
called Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) with the
aim of making remaining material derived from animal studies in biomedical research more
visible and accessible to the scientific community. We encourage journals, funding bodies,
and scientists to unite in promoting a new way of approaching animal research by adopting
the SEARCH framework.
Introduction
The contributions that animal models have made to biomedical research and their translation
to human health and welfare are undisputed. Many significant medical milestones, including
the development of antibiotics (e.g., penicillin [1]), vaccines (e.g., the polio vaccine [2]), medi-
cations for chronic diseases (e.g., insulin for diabetes [3]), surgical techniques (e.g., blood
transfusions and organ transplants [4]), and the development of breast cancer therapies such
as tamoxifen and trastuzumab (Herceptin) [5–7], have all been achieved because of break-
throughs made possible through using animals in research. However, these advances often
come at a high cost to biomedical researchers both financially and in time spent in develop-
ment. These research costs are increasing at a time when financial resources that governments,
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charities, and other funding organisations have available to support research remain static [8].
As it is unlikely that these financial restrictions will lift any time soon, researchers are encour-
aged to start thinking laterally about how they can increase the quality, depth, and impact of
their research in a low-cost, sustainable way. In addition to this, in most developed countries,
researchers who utilise animals in research are legally obliged to consider what are known as
the 3Rs in animal research: Replacement, Reduction and Refinement.
Current Trends in Animal Use in United Kingdom Biomedical Research
In order to gauge trends in the use of animals in biomedical research, we devised a Bristol
Online Survey (BOS), which was distributed electronically to over 100 biomedical researchers
representing more than 90 research institutes or groups. The questions posed aimed to estab-
lish how frequently animals were used in oncology, neuroscience, cardiology, and other disci-
plines and, if not used, if there was a benefit in pursuing this and the motivation behind that
choice. Key questions and responses are illustrated in Fig 1, with all ten questions posed listed
in S1 Appendix.
Of 135 respondents, 70% currently use animals in their research, and of those who do not,
70% wished to; thus, 90% of the total population surveyed would benefit from using animals in
their research. Our survey therefore suggests that the number of animals used in research
could rise over the coming years. This reflects the findings from the European Commission
that the net number of animals used across Europe in cardiovascular and oncology research
rose to 115,000 and 250,000, respectively, between 2008 and 2011 [9]. From our survey, the
main motivations behind wanting to incorporate animal models included a perceived benefit
to the depth and quality of the research. However, there was also a perception or expectation
that an in vivo component is needed to obtain funding and to publish in high-impact journals.
Fig 1. Summary of responses to our Bristol Online Survey. Participants were asked (A) if they used animals in
research, their type (GEM, genetically engineered mouse; PDX, patient-derived xenograft), and if their work would
benefit from an in vivo component; (B) if they stored surplus material; (C) if they would be willing to share this material;
and (D) if they would support a SEARCH initiative.
doi:10.1371/journal.pbio.2000719.g001
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This predicted rise in the use of animals in research is likely to be of concern to groups and
government organisations focussed on implementing the 3Rs.
For survey respondents who do not use animals currently but wished to do so, the main rea-
sons listed included lack of access to tissue and/or technical expertise and financial constraints.
As most of those using animal models had surplus archival material, this led us to consider if it
might be possible to find a way to facilitate the removal of these barriers without the need to
use more animals.
Developing the SEARCH Framework
Clearly many researchers are already addressing the 3Rs; however, concerns have been raised
in the community about their appropriate implementation. For example, in some instances,
the number of animals has been reduced to such an extent that there are concerns this may be
compromising the robustness of experimental data being generated [10].
Our BOS highlighted that there is significant surplus material generated from most animal
studies. This is often archived in-house, stored indefinitely, and frequently never revisited,
hence representing a considerable untapped resource; in our survey, two-thirds of respondents
currently using animals in their research reported storing excess tissue upon study completion.
Encouragingly, 95% of the researchers surveyed were willing to share this material on a collab-
orative basis. It would make economic, ethical, and academic sense to explore the option to
utilise this precious resource in the first instance, before generating new/additional animal
models and associated samples, if they already exist elsewhere [11].
To bring together those requiring animal tissue and those holding this type of archival
material, we have devised a framework called Sharing Experimental Animal Resources, Coor-
dinating Holdings (SEARCH) with the aim of making leftover material derived from animal
studies in biomedical research more visible and accessible to the scientific community [12].
The SEARCH framework contains four policies, described below and illustrated in Fig 2.
1. Share surplus tissue. Crucial to the success of the SEARCH framework is willingness of
researchers to share their archived reserves with the research community. Sharing resources
has the potential to foster new collaborations, which may not be immediately apparent
Fig 2. Diagram of the SEARCH framework to connect researchers, share materials, and accelerate
discovery whilst reducing animal use.
doi:10.1371/journal.pbio.2000719.g002
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through current networks, hence increasing research impact. These benefits come at mini-
mum cost to the group requiring the material and mean that the investment by the person
who has developed the material has added value.
2. Source tissue. SEARCH facilitates a web-based database through which scientists can
search and identify models that best fit their planned research. This echoes Shared Ageing
Research Models (ShARM; http://www.ShARMUK.org), an online resource that facilitates
access to aged murine models and their tissues. However, unlike SEARCH, ShARMUK col-
lects, stores, and distributes tissues from aged murine models through its biorepository and
maintains a database of live ageing mouse colonies. With SEARCH, the burden of maintaining
expensive colonies and storing materials, plus their associated costs, is relieved. SEARCH acts
as a free, no-cost partnership broker for those looking for material by connecting them to
those who have suitable archived samples. Any associated material transfer agreements and
other considerations (e.g., how the tissues may have been fixed or stored and authorship inclu-
sion agreements) are up to the respective researchers and their institutions. SEARCH will
enable those who lack in vivo expertise or infrastructure the ability to perform experiments
without the need to start from first principles, saving considerable time and resources.
3. Accelerate research. An important part of the SEARCH ethos is the generation of net-
works of researchers who are willing to connect and share their expertise and resources.
SEARCH promotes collaboration over competition, and by doing so, we believe scientific dis-
coveries will be accelerated. Furthermore, in a funding-restricted climate, the ability to bypass
the high cost of generating complex animal models will save researchers time and money.
These collaborations are also enabling researchers to complete pilot data studies in a short
space of time with minimal resources that are being used to strengthen grant applications, aid-
ing early-career researchers in accelerating their careers.
4. Reduce animal use. At the crux of the SEARCH initiative is the belief that high-quality
research can still be achieved whilst reducing the number of animals used in biomedical
research. This can be achieved by preferentially using suitable archived material, without the
need to generate unnecessary new models, also helping to maintain the robustness of results
whilst using fewer animals.
SEARCHBreast: The First SEARCH Prototype
The SEARCH initiative requires two crucial pieces of infrastructure: a secure database whereby
researchers can enter information about material available to share and an accompanying web-
site to host the database. We have developed this for our prototype, SEARCHBreast (https://
searchbreast.org/; https://www.youtube.com/watch?v=F_1mDBjEHe4), launched in 2014.
This has resulted in sign-ups from over 220 scientists to date, from the UK, European Union,
United States, and Australia, who all support the ethos of sharing resources and expertise to
accelerate breast cancer research [12].
The SEARCHBreast portfolio contains tissues from xenograft and genetically engineered
models and also includes an extensive range of patient-derived xenograft (PDX) models. In
light of the recent decision by the US National Cancer Institute (NCI) to replace their NCI-60
cell line screen with PDX models [13], it is pertinent that breast PDX models are made avail-
able to the community, particularly as these can be difficult to produce, requiring direct access
to human clinical material to establish, and come at a high cost to generate and maintain over
a long period of time. To our knowledge, SEARCHBreast is currently one of the only freely
accessible resources from which PDX models are available to share on a no-cost, collaborative
basis, which is clearly advantageous to the breast cancer community. As of 31 October 2016,
86 animal models were available through SEARCHBreast, representing thousands of ready-to-
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use tissue samples, including formalin-fixed paraffin-embedded tissue blocks, cells, and histo-
logical slides [12].
The Potential of the SEARCH Framework
Using SEARCHBreast as an example, the benefits of using the SEARCH framework are shown
in Fig 3. For example, the Blg-Cre:Brca1f/f:Trp53+/- genetic model of breast cancer (available
on the SEARCHBreast database) would require an extensive breeding programme just to gen-
erate a single mouse with the required phenotype, which may take up to 18 months to manifest
and be of considerable expense [14]. By contrast, accessing this tissue from SEARCHBreast
reduces this to a matter of weeks, with no further animals required, at a considerably lower
cost and requiring only those reagents needed for the experiments.
Since its inception in 2014, SEARCHBreast has facilitated the sharing of hundreds of tissue
samples from a range of different types of models. This has resulted in sparing 400 animals,
including those which would have been culled during transgenic breeding programmes. We
predict this number will rise significantly with increasing awareness and adoption of the
resource by the scientific community. Consequently, not only does SEARCHBreast have the
capacity to save researchers time and money whilst increasing the potential impact of their
research, but it addresses the reduction arm of the 3Rs. Similarly, it also aims to address
replacement and refinement. The SEARCHBreast website contains links to resources,
Fig 3. SEARCH discovery pipeline. (A) Traditional experimental workflow for in vivo research. (B)
Advantages of utilising the faster and more streamlined SEARCH workflow. (C) Case study 1 showing the
advantages of using models deposited in SEARCHBreast. (D) Case study 2 with an example of how
SEARCH can accelerate tissue sharing and experimental discovery.
doi:10.1371/journal.pbio.2000719.g003
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designed to ensure that researchers are well versed on the latest refinement measures in animal
studies. Additionally, SEARCHBreast is committed to promoting the uptake of emerging tech-
nologies, e.g., through 3D tissue modelling [15], which may reduce, or even replace, the need
for animals in research and instead promote a focus on using human tissues and cells available
via biorepositories such as the Breast Cancer Now Tissue Bank cell culture programme (http://
www.breastcancertissuebank.org/) or the Komen Tissue Bank (http://komentissuebank.iu.
edu/). Indeed, the SEARCHBreast team held a workshop on 3D breast cancer modelling in
May 2015 to promote this type of work, with many of the presentations available on the web-
site (https://searchbreast.org/) and the workshop proceedings published as well [15].
Summary
With a perception that animal models are required to generate high-impact publications, a
mind-set that will be challenging to reverse and which is beyond the scope of this article, the
SEARCH framework offers a fresh way of thinking about in vivo research. As exemplified by
those who have signed up to SEARCHBreast and in our BOS that addressed wider disease
types, there is support by the scientific community for the complementary approach to animal
research we are proposing. Furthermore, the platform we have developed for SEARCHBreast
is sufficiently generic to allow easy expansion into other disease types.
Despite recognised benefits in sharing resources, there is often some reluctance by scientists
to adopt this fully [16]. We believe that engagement with the breast cancer community from the
project’s inception was crucial to our success in establishing SEARCHBreast. This was an itera-
tive process to ensure we developed a resource that was fit for purpose for the research commu-
nity and would be embraced by them. Furthermore, by making the resource open to all—
researchers do not need to deposit a model to be able to use SEARCHBreast—we have promoted
inclusivity. Further still, both parties can benefit: the depositor sees his/her model(s) put to addi-
tional use and may gain added value in terms of publications, while the user has access to mate-
rials that would otherwise be costly and time consuming for him/her to develop from scratch,
thus overcoming some of the practical barriers that may be associated with resource sharing.
On the back of the success of SEARCHBreast and akin to the ARRIVE guidelines, which
encourage comprehensive reporting on experiments and outcomes of research in animals
[17], we would like to recommend that funding bodies support building the SEARCH frame-
work to encourage appropriate cataloguing and storing of surplus materials, at the same time
encouraging researchers to log their surplus materials at the conclusion of animal studies to
make this visible and accessible to others. While data sharing plans are frequently requested at
the time of submitting a funding application, details on what happens to surplus animal mate-
rials and how these may serve the wider research community at the conclusion of a project
tend to be overlooked, despite recommendation from experts to do so [18]. As such we present
a checklist that funding bodies might consider to assist in the grant evaluation process (S2
Appendix). We invite the PLOS Biology readership to adopt the SEARCH blueprint and unite
in sharing animal tissues in a more effective way.
Supporting Information
S1 Appendix. Proposed checklist for funding bodies to consider for research involving ani-
mal models.
(DOCX)
S2 Appendix. Questions posed in the Bristol Online Survey.
(DOCX)
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